Aethlon Medical Earnings Call Transcripts
Fiscal Year 2026
-
An Australian oncology trial is advancing to its final cohort after positive safety review, focusing on optimizing Hemopurifier treatments for patients unresponsive to leading immunotherapies. Data on immune and exosome changes are expected this quarter.
-
Hemopurifier, a unique device targeting cancer-related EVs, is progressing through a safety trial in Australia with positive early data and a strong cash position. Key milestones include advancing to an efficacy trial and seeking strategic partnerships for broader development.
-
Hemopurifier clinical trials are advancing in Australia, focusing on solid tumor patients unresponsive to immunotherapy. Operational improvements and new patient recruitment strategies have accelerated progress, with key safety and efficacy data expected in the coming months.
-
Australian oncology trial for Hemopurifier advanced with strong patient recruitment and cost controls. Operating expenses fell 27% year-over-year for the nine-month period, and compatibility work with the SLAMB system could broaden future clinical use.
-
Q2 2026 saw a 48% reduction in operating expenses and progress in the Australian oncology trial, with cohort one showing positive safety data and cohort two recruitment underway. Focus remains on oncology and Long COVID, with ongoing efforts to optimize spending and accelerate trial enrollment.
-
First cohort of the Australian oncology trial completed with no serious adverse events; cost-saving measures reduced operating expenses by 32% year-over-year. Focus remains on advancing the Hemopurifier program in Australia, with additional funding needs anticipated.
Fiscal Year 2025
-
Clinical progress advanced with first oncology patients treated in Australia and regulatory approval in India. Operating expenses dropped 26% year-over-year, with $2.3M raised via warrant inducement. Focus remains on oncology, with preliminary trial data expected in the coming months.
-
Oncology trials are advancing in Australia and India, with key safety milestones approaching. Promising early results in long COVID research have led to a conference presentation and potential new applications for the device, supported by recent publications.
-
A medical device company with $4.8M cash and no debt is advancing oncology trials in Australia and India, focusing on patients unresponsive to standard therapies. Recent protocol improvements and published data on kidney transplantation may open new partnership opportunities.
-
Hemopurifier, a novel blood purification device, is advancing through oncology and virology trials, with protocol changes accelerating patient enrollment in Australia. Financial discipline has extended the cash runway, and key data from the first patient cohort is expected in the June quarter.
-
Operating expenses and net loss were halved year-over-year, with a $4.8M cash balance at quarter-end. Oncology trials in Australia and India are progressing, aided by protocol amendments to accelerate enrollment and a 43% Australian tax rebate on clinical costs.
-
Permanent CEO appointed as oncology trials advance in Australia and India, with first patients enrolled and a third site pending. Operating expenses fell 9% year-over-year, and a 43% Australian R&D tax credit is expected to offset future costs.
-
Key milestones were achieved in advancing oncology clinical trials, with full ethics approvals at two Australian sites and further international expansion planned. Operating expenses dropped 24% year-over-year, and the cash balance was $9.1 million as of June 30, 2024.
Fiscal Year 2024
-
A virtual healthcare conference featured updates on a blood filtration device targeting cancer patients unresponsive to immune checkpoint inhibitors, with clinical trials underway in Australia and India. Initial safety data is expected soon, with a focus on oncology and potential for future partnerships.
-
Advanced clinical trials for Hemopurifier in oncology are underway, with key ethics approval in Australia and additional site submissions planned. FY 2024 saw a slight increase in operating expenses and net loss, but cash position improved. Oncology remains the primary focus, with organ transplant and infectious disease applications also progressing.